Bacterial infections in paediatric patients with chemotherapy induced neutropenia

Journal of the Pakistan Medical Association

Volumn 54, Issue 5, 2004, Pages 237-243

  Mahmud, S ^a   Ghafoor, T ^a   Badsha, S ^a   Gul, M S ^a  

^a Peshawar Cantonment   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTINEOPLASTIC AGENT; CEFOPERAZONE; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; PHYSICAL EXAMINATION; PSEUDOMONAS AERUGINOSA; PUBLIC HOSPITAL; SALMONELLA TYPHI; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL INFECTIONS; CHILD, PRESCHOOL; FEMALE; HOSPITAL MORTALITY; HOSPITALS, MILITARY; HUMANS; MALE; NEUTROPENIA; ONCOLOGY SERVICE, HOSPITAL; PAKISTAN;

EID: 3142547037     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999;341:893-900.
2. Akpek G, Knight RD, Wright DG. Use of oral mucosal neutrophil counts to detect the onset and resolution of profound neutropenia following high-dose myelosuppressive chemotherapy. Am J Hematology 2003;72:13-19.
3. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62:1-15.
4. Baltic T, Schlosser E, Bedell MK. Neutropenic fever: one institution's quality improvement project to decrease time from patient arrival to initiation of antibiotic therapy. Clin J Oncol Nurs 2002;6:337-40.
5. Dubey AP, Singhal D, Prakash SK. Febrile episodes in childhood malignancies. Indian Pediatrics 2002;39:952-7.
6. De Lalla F. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Drugs 1997;53:789-803.
7. Donowitz GR, Maki DG, Crnich CJ, et al. Infections in the neutropenic patient - new views of an old problem. Hematology 2001;1:113-39.
8. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol 1997;99:580-8.
9. Viscoli C, Moroni C, Boni L, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991;13:397-404.
10. Schimpff SC, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocyptopenia. N Engl J Med 1971;204:1061-5.
11. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4.
12. Elting LS, Rubenstein EB, Rolston KVI, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observation from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.
13. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
14. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin N Am 2001;15:457-82.
15. Cohen J, Worsley AM, Goldman JM, et al. Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet 1983;24:1452-4.
16. Mutnick AH, Kirby JT, Jones RN. Cancer resistance surveillance program: initial results from hematology-oncology centers in North America. Ann Pharmacother 2003;37:47-56.
17. Burney IA, Farooqui BJ, Siddiqui T, et al. The spectrum of bacterial infections in febrile neutropenic patients: effect on empiric antibiotic therapy. J Pak Med Assoc 1998;48:364-7.
18. Naqvi SMA, Siraj K, Bhutta ZA. Febrile neutropenia in childhood malignant disorders; clinical correlates and prognostic factors. Pak Ped J 1996;20:29-32.
19. Fleischhacka G, Hartmanna C, Simona A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J. Antimicrob Chemother 2001;47;841-53.
20. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995;20:1217-28.
21. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
22. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231-42.
23. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999;29:508-14.
24. Feld R, DePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000;18:3690-8.
25. Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic patients. Ann Hematol 2000;79:152-7.
26. Malik I, Shaharyar. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia. J Pak Med Assoc 2002;52:15-8
27. Chuang YY, Hung IJ, Yang CP, et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002;21:203-9.
28. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1997;317:1692-8.
29. Rolston KVI, Berkley P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
30. Sepkowitz KA, Brown AE, Armstrong D. Empirical therapy for febrile, neutropenic patients: persistence of susceptibility of gram-negative bacilli to aminoglycoside antibiotics. Clin Infect Dis 1994;19:810-11.
31. Brown AE, Kiehn TE, Armstrong D. Bacterial resistance in the patient with neoplastic disease. Infect Dis Clin Pract 1995;4:136-44.
32. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25:551-73.
33. The EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
34. Ariffin H, Arasu A, Mahfuzah M, et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Paediatr Child Health 2001;37:38-43.
35. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - clinical Trial Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
36. Rubin M, Hathorn JW, Marshall D, et al. Gram positive infections and use of vancomycin in 550 episodes of fever and neutropenia. Ann Int Med 1988;108:30-5.
37. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999;29:503-7.
38. Bhatti FN, Burney IA, Moid MI, et al. Bacterial isolates from neutropenic febrile pediatric patients and their sensitivity patterns to antibiotics. J Pak Med Assoc 1998;48:287-90.
39. Karim M, Khan W, Farooqi B, et al. Bacterial isolates in neutropenic febrile patients. J Pak Med Assoc 1991;41:35-7.